Lilly Initiates Phase 1 Trial for Novel Kidney-Protective Weight-Loss Drug LY4064912

▎Armstrong

On September 3, 2025, Eli Lilly registered a Phase I clinical trial for LY4064912 for weight loss on the Clinicaltrials.gov website.

This Phase I clinical trial plans to enroll 144 healthy and obese subjects, with administration via subcutaneous or intravenous injection, and is expected to be completed in October 2026.

The primary endpoints include PK, weight loss, and renal function benefits. This new weight-loss drug is expected to simultaneously possess a mechanism of action that protects the kidneys.

Weight loss is a key therapeutic area for Eli Lilly, with several innovative drugs in the early clinical stages. Since the beginning of this year, there are more.Oral weight loss innovative drug LY4086940, injectable weight loss and kidney protection new drug LY4064912 has been advanced to clinical trials.

Summary

Eli Lilly has taken a comprehensive lead in the iterative competition of GLP-1 and, in doing so, ascended to become the world's top pharmaceutical company by market value. Tirzepatide is currently the most potent product on the market, while its next-generation small-molecule GLP-1 has successfully advanced to Phase III clinical trials for both diabetes and weight loss, despite being less efficacious than oral peptides. The GGG triple-target agonist is currently in Phase III clinical trials. Amidst the rapid advancements in GLP-1, Eli Lilly and Novo Nordisk have also begun actively developing weight-loss drugs based on new mechanisms.